Reducing the Risks: Managing CRS, ICANS, and Skin Reactions in Emerging Lung Cancer Therapies

Source: Pharmacy Times articles

Experts discuss BiTE therapy in treating lung cancers, focusing on innovative agents like tarlatamab and amivantimab, and their toxicity management.
Read More